Carlos Martins, principal investigator of the research group H4A of CINTESIS, was one of the specialists heard by the Observador in the framework of a report that aimed at clarifying if the alleged benefits of the citicoline in the treatment of fibromyalgia may have scientific basis.
In an interview, the CINTESIS researcher recalled that “if there was any plausibility of the efficacy of the drug, the companies [that produce drugs containing citicoline] would be interested in carrying a clinical trial.”
Read the full report here here.